

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

10 x 2 ml dose Folding Carton

10 x 2 ml dose Booklet Label

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Equip FT suspension for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Each 2 ml dose contains:

Equine influenza virus inactivated strains:

A/equine/Newmarket/77 (H7N7)	≥ 1.2 log ₁₀ HAI*
A/equine/Borlange/91 (H3N8)	≥ 2.1 log ₁₀ HAI*
A/equine/Kentucky/98 (H3N8)	≥ 2.4 log ₁₀ HAI*
Immunopurified Tetanus Toxoid	≥ 70 IU/ml**

* HAI: Haemagglutination Inhibition titre

** IU: International units

3. PACKAGE SIZE

10 x 2 ml

4. TARGET SPECIES

Horses.

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Intramuscular use.

7. WITHDRAWAL PERIODS

Withdrawal period: Zero days.

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

Store in a refrigerator (2 °C - 8 °C).

Protect from light.

Do not freeze.

Keep the container in the outer carton.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Zoetis UK Limited

14. MARKETING AUTHORISATION NUMBER

Vm 42058/5163

15. BATCH NUMBER

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS**
2 ml Single Dose Syringe Label

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Equip FT

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Each 2 ml dose contains:

Inactivated Newmarket/77, Borlange/91, Kentucky/98, *C. tetani* toxoid

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Equip FT suspension for injection

2. Composition

Each 2 ml dose contains:

Active substances:

Equine influenza virus inactivated strains:

A/equine/Newmarket/77 (H7N7)	≥ 1.2 log ₁₀ HAI*
A/equine/Borlange/91 (H3N8)	≥ 2.1 log ₁₀ HAI*
A/equine/Kentucky/98 (H3N8)	≥ 2.4 log ₁₀ HAI*
Immunopurified Tetanus Toxoid	≥ 70 IU/ml**

* HAI: Haemagglutination Inhibition titre

** IU: International units

Adjuvants:

Quillaic Acid derivative (Quil A)

Aluminium phosphate

Clear liquid suspension above a whitish grey sediment which resuspends readily on shaking.

3. Target species

Horses.

4. Indications for use

For the active immunisation of horses of 5 months of age or older against Equine Influenza of H7N7 and H3N8 types (European or American strains, including Florida sublineage Clade 1 and Clade 2 isolates) to reduce clinical signs and virus excretion after infection, and against tetanus to prevent mortality.

Duration of immunity: 1 year and 3 months for influenza and 3 years for tetanus.

Onset of immunity: within 2 weeks of completion of the primary course.

5. Contraindications

None.

6. Special warnings

Special warnings:

Vaccinate healthy animals only.

The efficacy of active immunisation of young foals against equine influenza and tetanus will be influenced by the level of maternally derived antibodies. This will vary between individuals due to a number of factors, e.g. the immune status of the dam, adequacy of colostrum intake by the foal, etc. The vaccine should not be used in foals below 5 months of age, and foals should not be vaccinated until maternally derived antibodies have fallen below protective levels.

In any animal population, there may be a small number of individuals which fail to respond fully to vaccination. Successful vaccination depends upon correct storage and administration of the vaccine and the ability of the animal to respond. This can be influenced by such factors as genetic constitution, intercurrent infection, age, nutritional status, concurrent drug therapy and stress.

Special precautions for safe use in the target species:

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy:

The vaccine may be used in pregnant mares which have been vaccinated against both influenza and tetanus before pregnancy.

Heavily pregnant mares should not be subject to undue stress when vaccinated.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.

Overdose:

Accidental overdosage is unlikely to cause any reactions other than those described under Adverse events below.

Major incompatibilities:

Do not mix with any other veterinary medicinal product.

7. Adverse events

Horses:

Rare (1 to 10 animals / 10,000 animals treated):	Injection site swelling ^{1,3} Stiffness ¹ Elevated temperature ^{1,2}
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Injection site pain Hypersensitivity reaction ⁴ Anorexia, Lethargy

¹ This condition normally resolved by the day following vaccination.

² Mild, transient, typically 9-12 hours post vaccination.

³ Local, small (10-20 mm in diameter), soft, non-painful.

⁴ In the event of an allergic or anaphylactic reaction, immediate treatment should be given with a soluble glucocorticoid intravenously or adrenalin intramuscularly.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

E-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Dose: 2 ml

Administration: The veterinary medicinal product should be shaken thoroughly before use and administered by deep intramuscular injection.

Vaccination schedule: For protection against equine influenza and tetanus, the veterinary medicinal product should be used as follows:

Primary course	First dose	EQUIP FT 6 week interval
	Second dose	EQUIP FT 5 month interval
Boosters	1st booster	EQUIP F 12-15 month interval
	2nd booster	EQUIP F 12-15 month interval
	3rd booster	EQUIP FT

Thereafter, booster doses of Equip FT or Equip F should be administered so that the interval between vaccinations against influenza is not more than 15 months and the interval between vaccinations against tetanus is not more than 36 months.

9. Advice on correct administration

The routine practice of administering booster doses annually may remain the most convenient, even though protection against equine influenza has been demonstrated by challenge studies 15 months following the third vaccination (first booster dose). No field challenge studies have been carried out prior to the third vaccination; instead, efficacy was evaluated by serology which showed titres equivalent to those found in horses protected against challenge at 15 months.

It is recommended that a single booster dose should only be administered to horses that have already received a full primary course using vaccines that contain the same types of equine influenza virus included in this vaccine. A full primary course may be considered necessary in horses that have not been suitably primed.

10. Withdrawal periods

Zero days.

11. Special storage precautions

Keep out of the sight and reach of children.

Store in a refrigerator (2 °C - 8 °C).

Protect from light.

Do not freeze.

Keep the container in the outer carton.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and on the carton. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 42058/5163

Box of 10 single-dose vials.

Each box contains 10 sterile disposable 2 ml syringes and 10 sterile needles.

Box of 10 single-dose prefilled syringes with needles.

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse reactions:

Zoetis UK Limited
1st Floor, Birchwood Building
Springfield Drive
Leatherhead
Surrey
KT22 7LP
Phone: +44 (0) 345 300 8034

Manufacturer responsible for batch release:

Zoetis Belgium
Rue Laid Burniat 1
1348 Louvain-La-Neuve
Belgium

17. Other information

The veterinary medicinal product stimulates active immunity against equine influenza virus and tetanus by eliciting both a cell mediated immune response and a humoral response.

Further information on the protection afforded by vaccination:

Onset of immunity has been demonstrated by virulent challenge for Equine Influenza strains A/equine/Newmarket/1/93 (American lineage H3N8), A/equine/South Africa/4/03 (Florida sublineage Clade 1 of the American lineage H3N8), A/equine/Sydney/2888-8/07 (Florida sublineage Clade 1 of the American lineage H3N8) and A/equine/Richmond/1/07 (Florida sublineage Clade 2 of the American lineage H3N8).

Duration of immunity has been demonstrated by virulent challenge for Equine Influenza strains A/equine/Sussex/89 (Eurasian lineage H3N8) and A/equine/Newmarket/2/93 (Eurasian lineage H3N8).

Protection afforded by vaccination is additionally demonstrated by serology for Equine Influenza strains A/equine/Newmarket/77 (H7N7), A/equine/Brentwood/79 (Eurasian lineage H3N8), A/equine/Borlange/91 (Eurasian lineage H3N8), A/equine/Kentucky/98 (American lineage H3N8), A/equine/Newmarket/1/93 (American lineage H3N8), A/equine/Newmarket/2/93 (Eurasian lineage H3N8), A/equine/South Africa/4/03 (Florida sublineage Clade 1 of the American lineage H3N8), A/equine/Sydney/2888-8/07 (Florida sublineage Clade 1 of the American lineage H3N8) and A/equine/Richmond/1/07 (Florida sublineage Clade 2 of the American lineage H3N8).

POM-V

Gavin Hall

Approved: 23 September 2025